586 related articles for article (PubMed ID: 30473026)
1. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
Yan Z; Miao X; Zhang B; Xie J
Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
[TBL] [Abstract][Full Text] [Related]
2. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
3. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
5. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.
Tomita K; Teratani T; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Nishiyama K; Mataki N; Irie R; Minamino T; Okada Y; Kurihara C; Ebinuma H; Saito H; Shimizu I; Yoshida Y; Hokari R; Sugiyama K; Hatsuse K; Yamamoto J; Kanai T; Miura S; Hibi T
J Hepatol; 2012 Oct; 57(4):837-43. PubMed ID: 22641095
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
7. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of the Y220C mutant p53 against steatosis: good news?
Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
[TBL] [Abstract][Full Text] [Related]
10. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.
Chambel SS; Santos-Gonçalves A; Duarte TL
Biomed Res Int; 2015; 2015():597134. PubMed ID: 26120584
[TBL] [Abstract][Full Text] [Related]
11. Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance.
Qiu Y; Sui X; Zhan Y; Xu C; Li X; Ning Y; Zhi X; Yin L
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):978-990. PubMed ID: 28153708
[TBL] [Abstract][Full Text] [Related]
12. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
13. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
15. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
[TBL] [Abstract][Full Text] [Related]
16. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
17. Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
Lim JW; Dillon J; Miller M
World J Gastroenterol; 2014 Jul; 20(26):8325-40. PubMed ID: 25024592
[TBL] [Abstract][Full Text] [Related]
18. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
20. Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
Rosso N; Chavez-Tapia NC; Tiribelli C; Bellentani S
World J Gastroenterol; 2014 Jul; 20(27):9038-49. PubMed ID: 25083077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
